2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1
  5. PD-1/PD-L1 Inhibitor

PD-1/PD-L1 Inhibitor

PD-1/PD-L1 Inhibitors (194):

Cat. No. Product Name Effect Purity
  • HY-P9904
    Atezolizumab
    		Inhibitor 98.98%
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P9902
    Pembrolizumab
    		Inhibitor 99.06%
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P99144
    Anti-Mouse PD-1 Antibody (RMP1-14)
    		Inhibitor
    Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG2a antibody inhibitor.
  • HY-16141
    Cilengitide
    		Inhibitor 99.80%
    Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
  • HY-P9903
    Nivolumab
    		Inhibitor 99.63%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P99144A
    Anti-Mouse PD-1 Antibody (S-5001)
    		Inhibitor
    Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse PD-1 IgG1 antibody inhibitor.
  • HY-P10375
    BMS-986189
    		Inhibitor
    BMS-986189 is a macrocyclic peptide inhibitor of PD-L1 (IC50: 1.03 nM), and can be used for cancer research.
  • HY-100022A
    Tomivosertib hydrochloride
    		Inhibitor
    Tomivosertib hydrochlorideis a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib hydrochloride treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib hydrochloride also dramatically downregulates PD-L1 protein abundance.
  • HY-P99145
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
    		Inhibitor 99.60%
    Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1.html" class="link-product" target="_blank">PD-L1 IgG2b antibody inhibitor derived from host rat.
  • HY-19991
    BMS-1
    		Inhibitor 99.56%
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
  • HY-19745
    BMS-202
    		Inhibitor 99.39%
    BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
  • HY-P9919
    Durvalumab
    		Inhibitor 99.60%
    Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
  • HY-100022
    Tomivosertib
    		Inhibitor 99.92%
    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance.
  • HY-78695
    JQ-1 (carboxylic acid)
    		Inhibitor 99.82%
    JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.
  • HY-P9902A
    Pembrolizumab (anti-PD-1)
    		Inhibitor 99.90%
    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.
  • HY-108730
    Avelumab
    		Inhibitor 99.30%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-P99052
    Tislelizumab
    		Inhibitor 98.10%
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma.
  • HY-P9993
    Peresolimab
    		Inhibitor 99.62%
    Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis.
  • HY-P9971
    Camrelizumab
    		Inhibitor 98.80%
    Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.
  • HY-P9997
    Rosnilimab
    		Inhibitor 99.19%
    Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1.